Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Ea Pharma Co. Ltd.
Headquarters: Tokyo, Japan
Website: http://www.eapharma.co.jp/en/...
Year Founded: 2016
Status: Private
BioCentury | Aug 22, 2024
Finance
Venture Report: Megarounds for BridgeBio newco, Pathalys and the latest from Versant
$300M raise for rare disease company GondolaBio headlines the week’s biggest venture rounds
BioCentury | Jun 28, 2024
Finance
Venture Report: Curie.Bio’s fund; megarounds for Formation, EvolutionaryScale, BillionToOne
Plus: New fundings for Exsilio, TwoStep and Augustine
BioCentury | Jan 18, 2023
Finance
Carlyle, Abingworth again testing Launch model with Pathalys’ kidney disease asset
Leading $150M round, PE-backed venture firm will draw on clinical expertise of organization set up to advise on late-stage trials
BioCentury | Mar 29, 2022
Regulation
March 28 Quick Takes: Japan approvals include Sanofi’s Xenpozyme for rare disease
Plus more bad news for ALS and Biogen, Eagle acquiring Acacia, and more
BioCentury | Apr 8, 2021
Finance
With $95M second fund and incubator, Japan-focused Remiges helps start-ups take flight
Cross-border firm to launch newcos out of Japanese academia
BioCentury | Feb 27, 2019
Finance
Calypso finds its rhythm
How rising interest in IL-15 helped six-year-old Calypso close its series A
Items per page:
1 - 10 of 15